|
|
|
|
|
|
Sponsored by: |
Eisai Limited |
Information provided by: | Eisai Medical Research Inc. |
ClinicalTrials.gov Identifier: | NCT00103948 |
This is an 18-week, prospective, multi-center, randomized, double-blind, placebo-controlled, (1:1) parallel-group study.
Condition | Intervention | Phase |
Cognitive Impairment |
Drug: Aricept |
Phase II |
Genetics Home Reference related topics: | cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy |
ChemIDplus related topics: | Donepezil E 2020 |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment |
Ages Eligible for Study: | 25 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Peripheral vascular disease must have been stable for 12 weeks prior to Screening. No elective surgical procedures should be planned during the course of the study (e.g., hernia repair and bunion removal). Patient with diabetes must be stable as demonstrated by an HbA1c of <= 8.0% or a random serum glucose value of <= 170 mg/dL.
Exclusion Criteria:
United States, Illinois | |||||
Jose Biller, M.D. | |||||
Maywood, Illinois, United States, 60152 | |||||
United States, New York | |||||
New York University School of Medicine | |||||
New York, New York, United States, 10016 | |||||
Australia, South Australia | |||||
Woodville, South Australia, Australia, 5011 | |||||
Spain | |||||
Malaga, Spain, 29010 |
Eisai Limited |
Study Director: | Margaret Moline, Ph.D. | Eisai Medical Research Inc. |
Study ID Numbers: | E2020-A001-233 |
First Received: | February 17, 2005 |
Last Updated: | October 3, 2007 |
ClinicalTrials.gov Identifier: | NCT00103948 |
Health Authority: | United States: Food and Drug Administration; European Union: European Medicines Agency |
|